Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer (Q39601530)

13 September 2017

Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer (English)

1 reference

13 September 2017

1 reference

Andrew J Stephenson

1

1 reference

13 September 2017

Armen G Aprikian

2

1 reference

13 September 2017

Luis Souhami

3

1 reference

13 September 2017

Hassan Behlouli

4

1 reference

13 September 2017

Avrum I Jacobson

5

1 reference

13 September 2017

Louis R Bégin

6

1 reference

13 September 2017

Simon Tanguay

7

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

13 September 2017

1 reference

13 September 2017

59

1 reference

13 September 2017

5

1 reference

13 September 2017

652-656

1 reference

Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening

13 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Results of conservative management of clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Relationship between changes in prostate-specific antigen and prognosis of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a 'rapid riser' subset

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Clinical significance of repeat sextant biopsies in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901526-1

7 January 2021

10.1016/S0090-4295(02)01526-1

Identifiers

DOI

1 reference

13 September 2017

1 reference